Dr. Davendra P. Sohal, MD, MPH
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 84
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35099016
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
- West Chester Hospital West Chester, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 84
- Services billed
- 291
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 188 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 39 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 38 | 38 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Cincinnati, OH | 25 |
| Prochlorperazine Maleate Other prescribers in Cincinnati, OH | 25 |
| Oxycodone Hcl Other prescribers in Cincinnati, OH | 14 |
| Ondansetron Hcl Other prescribers in Cincinnati, OH | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 17 payments worth $16,837 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $9,840 |
|---|---|
| Incyte Corporation | $3,924 |
| Corcept Therapeutics | $3,019 |
| AbbVie Inc. | $35.57 |
| Alcresta Therapeutics, Inc. | $19.19 |
| Compensation for services other than consulting (speaking, faculty) | $16,008 |
|---|---|
| Travel and Lodging | $469 |
| Food and Beverage | $361 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,920 |
| AstraZeneca Pharmaceuticals LP Aug 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,280 |
| Incyte Corporation Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) | $2,740 |
| Corcept Therapeutics Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology Company’s descriptionPayment: Ad Board | $2,400 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,640 |
| Incyte Corporation Feb 7, 2025 | Compensation for services other than consulting (speaking, faculty) Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) | $685 |
| Corcept Therapeutics Jan 22, 2025 | Travel and Lodging Korlym · Endocrinology · travel to San Francisco, CA · in-kind Company’s descriptionTravel: Ad Board | $418 |
| Incyte Corporation Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) | $343 |
| Corcept Therapeutics Jan 22, 2025 | Travel and Lodging Korlym · Endocrinology · travel to San Francisco, CA · in-kind Company’s descriptionTravel: Ad Board | $22.00 |
| Incyte Corporation Mar 19, 2025 | Travel and Lodging Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) · travel to Cincinnati, OH | $21.00 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,920 |
| AstraZeneca Pharmaceuticals LP Aug 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,280 |
| Incyte Corporation Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) | $343 |
| Incyte Corporation Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) | $2,740 |
| Incyte Corporation Mar 19, 2025 | Travel and Lodging Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) · travel to Cincinnati, OH | $21.00 |
| Incyte Corporation Mar 19, 2025 | Travel and Lodging Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) · travel to Cincinnati, OH | $8.00 |
| Incyte Corporation Feb 7, 2025 | Compensation for services other than consulting (speaking, faculty) Pemazyre · Hepatology (Liver, Pancreatic, Gall Bladder) | $685 |
| Corcept Therapeutics Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology Company’s descriptionPayment: Ad Board | $2,400 |
| Corcept Therapeutics Jan 22, 2025 | Travel and Lodging Korlym · Endocrinology · travel to San Francisco, CA · in-kind Company’s descriptionTravel: Ad Board | $418 |
| Corcept Therapeutics Jan 22, 2025 | Travel and Lodging Korlym · Endocrinology · travel to San Francisco, CA · in-kind Company’s descriptionTravel: Ad Board | $22.00 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,640 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 9 companies. The companies reported $1,836,707 in research payments for these studies, mostly to the institutions running them.
- Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC
Genentech, Inc. - A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05578092 - A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04626635 - A phase 1 openlabel study of PF07934040 as a single agent and in combination with other targeted agents in participants with advanced solid tumors harboring mutations in the kras gene
Pfizer Inc. - A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04420884 - MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company · Active, not recruiting · NCT06586515 - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - A Phase I/II First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
E.r. Squibb & Sons, L.l.c. - My Pathway
Genentech, Inc. - A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response …
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.